NCT00651352View on ClinicalTrials.gov

A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Healthy Volunteer Smokers

Interventions

DRUG

4 mg nicotine lozenge

marketed formulation

DRUG

2 mg nicotine lozenge

marketed formulation

DRUG

2 mg nicotine prototype

2 mg

DRUG

4 mg nicotine prototype

4 mg

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY